natgillin/translations-raw huggingface dataset:
In case of diarrhoea, make sure that you drink enough water. 
V primeru driske poskrbite, da popijete dovolj vode.
Steady-state is reached within three to four days. 
Stabilno stanje se doseže v treh do štirih dneh.
The absolute oral bioavailability is >90%. 
Absolutna biološka uporabnost je > 90 %.
This effect is too small to be clinically relevant. 
Ta učinek je prešibek, da bi bil klinično pomemben.
Non-renal elimination contributes to about 35% of total elimination. 
Neledvično izločanje prispeva k okoli 35 % skupnega izločanja.
- Tell your doctor if you are pregnant or planning to become pregnant. 
- Obvestite svojega zdravnika, če ste noseči ali načrtujete zanositev.
This effect can be attributed to a diminished renal function in older people. 
Ta učinek je mogoče pripisati zmanjšani ledvični funkciji pri starejših.
Date of first authorisation: 15 October 2009 Date of latest renewal: 06 June 2014 
Datum prve odobritve: 15. oktober 2009 Datum zadnjega podaljšanja: 06. junij 2014
The mechanism for this interaction is not clear. 
Mehanizem tega medsebojnega delovanja ni znan.
Long-term study 
Dolgotrajna študija
Decreased appetite 
Pogosti zmanjšan apetit
Overall, the safety profile of Resolor in children was the same as in adults. 
Na splošno je bil varnostni profil zdravila Resolor pri otrocih enak kot pri odraslih.
The doctor may want to reassess your condition and the benefit of continued treatment after the first 4 weeks and thereafter at regular intervals. 
Zdravnik bo morda hotel ponovno oceniti vaše stanje in koristi nadaljnjega zdravljenja po prvih štirih tednih in nato v rednih razmikih.
Just take your next dose at the usual time. 
Preprosto nadaljujte z naslednjim odmerkom ob običajnem času.
It acts on the muscle wall of the gut, helping to restore the normal functioning of the bowel. 
Deluje na mišično steno črevesa in pomaga ponovno vzpostaviti normalno delovanje črevesa.
What Resolor is and what it is used for 
Kaj je zdravilo Resolor in za kaj ga uporabljamo
- Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, 
- Perforacija ali obstrukcija črevesa zaradi strukturne ali funkcijske okvare črevesne stene,
As with any new symptom, patients should discuss the new onset of palpitations with their physician. 
Kot pri vseh novih simptomih se morajo bolniki o novem pojavu palpitacij pogovoriti s svojim zdravnikom.
Your doctor may also recommend a lower dose of one 1 mg tablet daily if you have severe kidney disease. 
Vaš zdravnik lahko priporoči tudi nižji odmerek od ene 1 mg tablete na dan, če imate hudo ledvično bolezen.
Unchanged active substance made up about 92-94% of the total radioactivity in plasma. 
Nespremenjena zdravilna učinkovina je predstavljala okoli 92-94 % celotne radioaktivnosti v plazmi.
If the intake of once daily prucalopride is not effective after 4 weeks of treatment, the patient should be re-examined and the benefit of continuing treatment reconsidered. 
Če vnos prukaloprida enkrat na dan ni učinkovit po 4 tednih zdravljenja, je treba bolnika ponovno pregledati in pretehtati koristi nadaljnjega zdravljenja.
Pharmacotherapeutic group: Other drugs for constipation, ATC code: A06AX05. 
Farmakoterapevtska skupina: druga zdravila proti zaprtju, oznaka ATC: A06AX05.
R107504, R084536 and R104065 (formed by O-demethylation) were identified as minor plasma metabolites. 
R107504, R084536 in R104065 (ki nastanejo z O-demetilacijo) so bili opredeljeni kot manjši presnovki v plazmi.
However, sometimes Resolor may cause dizziness and tiredness, especially on the first day of treatment, and this may have an effect on driving and use of machines. 
Vendar pa lahko včasih zdravilo Resolor povzroči vrtoglavico in utrujenost, predvsem prvi dan zdravljenja, to pa lahko vpliva na sposobnost upravljanja vozil in strojev.
In case of prolonged treatment, the benefit should be reassessed at regular intervals. 
V primeru dolgotrajnega zdravljenja je treba v rednih razmikih oceniti koristi.
The clinical significance or benefit of this mechanism of action when compared with other laxatives has not been investigated. 
Klinične pomembnosti ali koristi tega mehanizma delovanja v primerjavi z drugimi odvajali niso raziskali.
If you have very bad diarrhoea, the contraceptive pill may not work properly and the use of an extra method of contraception is recommended. 
Če imate zelo hudo diarejo, kontracepcijske tablete morda ne delujejo ustrezno in je priporočena uporaba dodatne kontracepcijske metode.
The usual dose of Resolor for most patients is one 2 mg tablet once a day. 
Običajni odmerek zdravila Resolor za večino bolnikov je ena 2 mg tableta enkrat na dan.
Fertility Animal studies indicate that there is no effect on male or female fertility. 
Študije na živalih kažejo, da ni vpliva na plodnost moških ali žensk.
The study is therefore considered to be inconclusive with respect to efficacy. 
Zato menijo, da iz te študije ni mogoče sklepati o učinkovitosti.
Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances. 
Zaradi velike izgube tekočine zaradi diareje ali bruhanja je morda potreben popravek elektrolitskih motenj.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je vaš zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte z njim.
Resolor with food and drink Resolor can be taken with or without food and drinks, at any time of the day. 
Zdravilo Resolor skupaj s hrano in pijačo Zdravilo Resolor lahko vzamete s hrano in pijačo ali brez nje ob katerem koli času dneva.
See the instructions in the patient leaflet of the contraceptive pill you are taking. 
Preberite navodila za uporabo kontracepcijskih tablet, ki jih uporabljate.
Manufacturer Sanico NV Veedijk 59 
Izdelovalec Sanico NV Veedijk 59
Paediatric population: Resolor should not be used in children and adolescents younger than 18 years (see section 5.1). 
Pediatrična populacija: zdravilo Resolor se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let (glejte poglavje 5.1).
The accumulation ratio after once daily dosing ranged from 1.9 to 2.3. 
Kopičenje po enkratnem dnevnem odmerku je segalo od 1,9 do 2,3.
Due to the specific mode of action of prucalopride (stimulation of propulsive motility), exceeding the daily dose of 2 mg is not expected to increase efficacy. 
Zaradi specifičnega načina delovanja prukaloprida (stimulacija propulzivne motilitete) se ne pričakuje, da bo povečanje dnevnega odmerka 2 mg povečalo učinkovitost.
Cases of spontaneous abortion have been observed during clinical studies, although, in the presence of other risk factors, the relationship to prucalopride is unknown. 
Med kliničnimi študijami so bili opaženi primeri spontanega splava, čeprav ob sočasni prisotnosti drugih dejavnikov tveganja povezava s prukalopridom ni znana.
Prucalopride has a low pharmacokinetic interaction potential. 
Prukaloprid ima nizek farmakokinetični interakcijski potencial.
Although prucalopride may be a weak substrate for P-glycoprotein (P-gp), it is not an inhibitor of P-gp at clinically relevant concentrations. 
Čeprav je prukaloprid lahko šibek substrat za P-glikoprotein (P-gp), ni zaviralec P-gp v klinično pomembnih koncentracijah.
Take Resolor every day for as long as your doctor prescribes it. 
Zdravilo Resolor jemljite vsak dan toliko časa, kot vam je predpisal vaš zdravnik.
In case of severe diarrhoea, the efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive). 
V primeru hude diareje se lahko učinkovitost peroralnih kontraceptivov zmanjša in se priporoča uporaba dodatne kontracepcijske metode, da bi preprečili morebitno neučinkovitost peroralne kontracepcije (glejte informacije, priložene peroralnemu kontraceptivu).
Renal excretion is the main route of elimination of prucalopride (see section 5.2). 
Ledvično izločanje je glavni način izločanja prukaloprida (glejte poglavje 5.2).
The majority of patients continued using prucalopride. 
Večina bolnikov je nadaljevala z uporabo prukaloprida.
What you need to know before you take Resolor 
Kaj morate vedeti, preden boste vzeli zdravilo Resolor
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (including pregnancy, embryonal/foetal development, parturition or postnatal development) (see section 5.3). 
Študije na živalih ne kažejo na neposredne ali posredne škodljive vplive na toksičnost za razmnoževanje (vključno z nosečnostjo, razvojem zarodka/plodu, porodom ali postnatalnim razvojem) (glejte poglavje 5.3).
Interactions of similar magnitude may be expected with other potent inhibitors of P-gp such as verapamil, cyclosporine A and quinidine. 
Interakcije podobnega obsega lahko pričakujemo pri drugih močnih zaviralcih P-gp, kot so verapamil, ciklosporin A in kinidin.
In the absence of human data in women who actively breast-fed while taking Resolor, a decision should be made whether to discontinue breast-feeding or to discontinue Resolor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Zaradi pomanjkanja podatkov pri ljudeh pri ženskah, ki med uporabo zdravila Resolor aktivno dojijo, se je treba odločiti med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Resolor, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. 
Ledvično izločanje nespremenjenega prukaloprida vključuje pasivno filtracijo in aktivni izloček.
If you are older than 65 years or have severe liver disease, the starting dose is one 1 mg tablet once a day, which your doctor may increase to 2 mg once a day if needed. 
Če ste starejši od 65 let ali imate hudo jetrno bolezen, je začetni odmerek ena 1 mg tableta enkrat na dan, ki ga lahko vaš zdravnik po potrebi poviša na 2 mg enkrat na dan.
If you have taken more Resolor than you should, it is possible that you will get diarrhoea, headache and/or nausea. 
Če ste vzeli več zdravila Resolor, kot bi smeli, boste morda dobili drisko, glavobol in/ali vam bo slabo.
If you stop taking Resolor If you stop taking Resolor, your constipation symptoms may come back again. 
Če ste prenehali jemati zdravilo Resolor Če ste prenehali jemati zdravilo Resolor, se lahko ponovno pojavijo simptomi zaprtja.
Other adverse reactions have been reported occasionally. 
Občasno se poroča o drugih neželenih učinkih.
Posology Adults: 2 mg once daily with or without food, at any time of day. 
Odmerjanje Odrasli: 2 mg enkrat na dan, s hrano ali brez nje, ob katerem koli času dneva.
Tremors, migraine 
Občasni tremor, migrena
Resolor has been shown not to cause rebound phenomena, nor to induce dependency. 
Pokazalo se je, da zdravilo Resolor ne povzroča povratnega fenomena ali odvisnosti.
Of these, over 1,500 patients received Resolor at the recommended dose of 2 mg per day, while approximately 1,360 patients were treated with 4 mg prucalopride daily. 
Od teh bolnikov jih je več kot 1.500 prejemalo zdravilo Resolor v priporočenem odmerku 2 mg na dan, medtem ko je bilo približno 1.360 bolnikov zdravljenih s 4 mg prukaloprida na dan.
Resolor may have a minor influence on the ability to drive and use machines, since dizziness and fatigue have been observed in clinical studies, particularly during the first day of treatment (see section 4.8). 
Zdravilo Resolor lahko ima blag vpliv na sposobnost vožnje in upravljanja s stroji, saj so v kliničnih študijah opazili vrtoglavico in utrujenost, predvsem prvi dan zdravljenja (glejte poglavje 4.8).
A thorough QT study was performed to evaluate the effects of Resolor on the QT interval at therapeutic (2 mg) and supratherapeutic doses (10 mg) and compared with the effects of placebo and a positive control. 
Izvedena je bila podrobna študija QT, da bi ocenili učinke zdravila Resolor na interval QT pri terapevtskem (2 mg) in supraterapevtskem odmerku (10 mg), ter primerjana z učinki placeba in pozitivne kontrole.
Resolor is unlikely to affect your ability to drive or use machines. 
Ni verjetno, da bi zdravilo Resolor vplivalo na vašo sposobnost upravljanja vozil in strojev.
Efficacy beyond three months has not been demonstrated in placebo-controlled studies (see Section 5.1). 
Učinkovitost zdravljenja, daljšega od treh mesecev, ni bila dokazana v študijah, nadzorovanih s placebom (glejte poglavje 5.1).
In a study in healthy volunteers, treatment with prucalopride was well tolerated when given in an up-titrating scheme up to 20 mg once daily (10 times the recommended therapeutic dose). 
V študiji z zdravimi prostovoljci je bila toleranca zdravljenja s prukalopridom dobra ob postopnem povečevanju odmerka do 20 mg enkrat na dan (10-kratni priporočeni terapevtski odmerek).
A human study has shown that prucalopride is excreted in breast milk. 
Študija pri ljudeh je pokazala, da se prukaloprid izloča v materino mleko.
A population pharmacokinetic analysis showed that the apparent total clearance of prucalopride was correlated with creatinine clearance, but that age, body weight, sex or race had no influence. 
Analiza populacijske farmakokinetike je pokazala, da je očitni skupni očistek prukaloprida soodvisen od očistka kreatinina, vendar pa starost, telesna masa, spol ali rasa niso imeli vpliva.
The pharmacokinetics of prucalopride is dose-proportional within and beyond the therapeutic range (tested up to 20 mg). 
Farmakokinetika prukaloprida je sorazmerna z odmerkom v terapevtskem razponu in izven njega (preskušeno do 20 mg).
Taking a higher dose than recommended will not make the product work better. 
Če jemljete večji odmerek zdravila, kot je priporočeno, zdravilo ne deluje boljše.
At therapeutic doses of Resolor, no effects on breast-fed newborns/infants are anticipated. 
Pri terapevtskih odmerkih zdravila Resolor se ne pričakuje učinkov na dojene novorojence/dojenčke.
This confirmed the results of two placebo controlled QT studies. 
To je potrdilo rezultate dveh s placebom nadzorovanih študij QT.
However, the totality of the data including the other double-blind placebo controlled 12 week studies support the efficacy of Resolor. 
Vendar podatki v celoti, vključno s tistimi iz drugih dvojno slepih, s placebom nadzorovanih, 12-tedenskih študij, podpirajo učinkovitost zdravila Resolor.
The plasma clearance of prucalopride averages 317 ml/min. 
Izločanje prukaloprida iz plazme znaša povprečno 317 ml/min.
Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. 
Če pride do prevelikega odmerjanja, je treba bolnika zdraviti simptomatsko in uvesti podporno zdravljenje, če je potrebno.
The safety profile of Resolor in this 24 week study was consistent with that seen in the previous 12 week studies. 
Varnostni profil zdravila Resolor v tej 24-tedenski študiji je skladen s tistim v prejšnjih, 12-tedenskih študijah.
Prucalopride is a dihydrobenzofurancarboxamide with gastrointestinal prokinetic activities. 
Prukaloprid je dihidrobenzofuran karboksamid z gastrointestinalnimi prokinetičnimi aktivnostmi.
Prucalopride is rapidly absorbed; after a single oral dose of 2 mg in healthy subjects, Cmax was attained in 2-3 hours. 
Prukaloprid se hitro absorbira; po enkratnem peroralnem odmerku 2 mg zdravim prostovoljcem je bila vrednost Cmax dosežena v 2-3 urah.
In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found. 
In vitro je jetrna presnova človeka zelo počasna in so bile odkrite samo manjše količine presnovkov.
There is a limited amount of data from the use of prucalopride in pregnant women. 
Podatki o uporabi prukaloprida pri nosečnicah so omejeni.
Effects of other medicinal products on pharmacokinetics of prucalopride Ketoconazole (200 mg twice daily), a potent inhibitor of CYP3A4 and of P-gp, increased the systemic exposure to prucalopride by approximately 40%. 
Učinki drugih zdravil na farmakokinetiko prukaloprida Ketokonazol (200 mg dvakrat na dan), močan zaviralec CYP3A4 in P-gp, je povečal sistemsko izpostavljenost prukalopridu za približno 40 %.
Each pack contains 7 x 1, 14 x 1, 28 x 1 or 84 x 1 film-coated tablet. 
Vsako pakiranje vsebuje 7 x 1, 14 x 1, 28 x 1 ali 84 x 1 filmsko obloženo tableto.
Not for use in children and adolescents younger than 18 years. 
Zdravilo ni primerno za uporabo pri otrocih in mladostnikih, starih manj kot 18 let.
Therapeutic doses of probenecid, cimetidine, erythromycin and paroxetine did not affect the pharmacokinetics of prucalopride. 
Terapevtski odmerki probenecida, cimetidina, eritromicina in paroksetina niso vplivali na farmakokinetiko prukaloprida.
What Resolor is and what it is used for What you need to know before you take Resolor How to take Resolor 
Kaj je zdravilo Resolor in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Resolor Kako jemati zdravilo Resolor Možni neželeni učinki
Prucalopride is extensively distributed, and has a steady-state volume of distribution (Vdss) of 567 litres. 
Prukaloprid se obsežno porazdeli in ima volumen porazdelitve v stanju dinamičnega ravnovesja (Vdss) 567 litrov.
Take special care with Resolor and tell your doctor if you: - suffer from severe kidney disease, - suffer from severe liver disease, - are currently under supervision by a doctor for a serious medical problem such as lung or heart disease, nervous system or mental health problems, cancer, AIDS or a hormonal disorder. 
Bodite posebno pozorni pri jemanju zdravila Resolor in povejte zdravniku, če: - imate hudo ledvično bolezen, - imate hudo jetrno bolezen, - ste trenutno pod nadzorom zdravnika zaradi resnega zdravstvenega stanja, kot so pljučna ali srčna bolezen, težave z živčevjem ali duševnim zdravjem, rak, AIDS ali hormonske motnje.
The side effects mostly occur at the start of treatment and usually disappear within a few days with continued treatment. 
Neželeni učinki se večinoma pojavijo ob začetku zdravljenja in običajno izzvenijo v nekaj dneh nadaljnjega zdravljenja.
The plasma protein binding of prucalopride is about 30%. 
Na plazemske beljakovine se veže približno 30 % prukaloprida.
Women of childbearing potential have to use effective contraception during treatment with prucalopride 
Ženske v rodni dobi Ženske v rodni dobi morajo med zdravljenjem s prukalopridom uporabljati učinkovito kontracepcijo.
In dogs, the effects observed in the gastrointestinal tract are sensitive to blockade with selective 5-HT4 receptor antagonists illustrating that the observed effects are exerted via selective action on 5-HT4 receptors. 
Pri psih so učinki, opaženi v prebavnem traktu, občutljivi na blokado s selektivnim antagonistom receptorja 5-HT4, kar kaže, da se opaženi učinki izvajajo prek selektivnega delovanja na receptorje 5-HT4.
Resolor is only for adults and should not be taken by children and adolescents up to 18 years. 
Zdravilo Resolor je namenjeno samo odraslim, zato ga ne smejo jemati otroci in mladostniki, mlajši od 18 let.
In double-blind clinical studies, the incidence of QT-related adverse events and ventricular arrhythmias was low and comparable to placebo. 
V dvojno slepih študijah je bila pogostnost s QT povezanih neželenih učinkov in ventrikularnih aritmij nizka in primerljiva s placebom.
Prucalopride is a selective, high affinity serotonin (5-HT4) receptor agonist, which is likely to explain its prokinetic effects. 
Prukaloprid je selektiven agonist z veliko afiniteto za serotoninski (5-HT4) receptor, kar verjetno razloži njegove prokinetične učinke.
In a small pharmacokinetic study, the Cmax and AUC of prucalopride were, on average, 10-20% higher in patients with moderate to severe hepatic impairment compared with healthy subjects (see sections 4.2 and 4.4). 
V majhni farmakokinetični študiji sta bila Cmax in AUC prukaloprida povprečno 10-20 % višja pri bolnikih z zmerno do hudo jetrno okvaro v primerjavi z zdravimi osebami (glejte poglavji 4.2 in 4.4).
Warnings and precautions Talk to your doctor before taking Resolor. 
Opozorila in previdnostni ukrepi Pred jemanjem zdravila Resolor se posvetujte s svojim zdravnikom.
After once daily dosing of 1 mg, peak plasma concentrations and AUC of prucalopride in older people were 26% to 28% higher than in young adults. 
Po enkratnem dnevnem odmerku 1 mg so bile najvišje plazemske koncentracije in AUC prukaloprida pri starejših osebah 26 % do 28 % višje kot pri mladih odraslih.
7 x 1 film-coated tablets 14 x 1 film-coated tablets 28 x 1 film-coated tablets 84 x 1 film-coated tablets 
7 x 1 filmsko obložena tableta 14 x 1 filmsko obložena tableta 28 x 1 filmsko obložena tableta 84 x 1 filmsko obložena tableta
In an oral dose study with radiolabelled prucalopride in man, small amounts of seven metabolites were recovered in urine and faeces. 
V študiji peroralnega odmerka z radioaktivno označenim prukalopridom pri človeku so bile v urinu in blatu odkrite majhne količine sedmih presnovkov.
Caution should be exercised when prescribing Resolor to patients with these conditions especially when used in patients with a history of arrhythmias or ischaemic cardiovascular disease. 
Pri predpisovanju zdravila Resolor bolnikom s temi stanji je potrebna previdnost, zlasti pri bolnikih z aritmijo ali ishemično boleznijo srca v anamnezi.
An extended series of safety pharmacology studies with special emphasis on cardiovascular parameters showed no relevant changes in haemodynamic and ECG derived parameters (QTc) with the exception of a modest increase in heart rate and blood pressure observed in anaesthetised pigs after intravenous administration, and an increase in blood pressure in conscious dogs after bolus intravenous administration, which was not observed either in anaesthetised dogs or after oral administration in dogs reaching similar plasma levels. 
Razširjena serija študij farmakološke varnosti s posebnim poudarkom na srčno-žilnih parametrih ni pokazala pomembnih sprememb hemodinamike in iz EKG izpeljanih parametrov (QTc), z izjemo majhnega povišanja srčnega utripa in krvnega tlaka, opaženih pri anesteziranih prašičih po intravenski uporabi, in povišanja krvnega tlaka pri psih pri zavesti po intravenskem bolusu, ki ni bilo opaženo pri anesteziranih psih ali po peroralni uporabi pri psih, ki so dosegli podobne plazemske ravni.
In all three studies, treatment with Resolor also resulted in significant improvements in a validated and disease specific set of symptom measures (PAC-SYM), including abdominal (bloating, discomfort, pain and cramps), stool (incomplete bowel movements, false alarm, straining, too hard, too small) and rectal symptoms (painful bowel movements, burning, bleeding/tearing), determined at week 4 and week 12. 
V vseh treh študijah je zdravljenje z zdravilom Resolor povzročilo tudi pomembno izboljšanje potrjenega in za bolezen specifičnega seta meril simptomov (PAC-SYM), vključno s trebušnimi (napihnjenost, nelagodje, bolečine in krči), simptomi, povezanimi z odvajanjem blata (nepopolno odvajanje, lažni alarm, napenjanje, pretrdo blato, premalo blata), in rektalnimi simptomi (boleče odvajanje, pekoč občutek, krvavitev/raztrganine), določenimi 4. in 12. teden.
Other metabolites identified and quantified in urine and faeces were R084536 (formed by N-dealkylation) accounting for 3% of the dose and products of hydroxylation (3% of the dose) and N-oxidation (2% of the dose). 
Drugi presnovki, opredeljeni in izmerjeni v urinu in blatu, so bili R084536 (nastane z Ndealkilacijo), ki predstavlja 3 % odmerka, ter produkti hidroksilacije (3 % odmerka) in N-oksidacije (2 % odmerka).
This study did not show significant differences between Resolor and placebo at either dose, based on mean QT measurements and outlier analysis. 
Študija ni pokazala pomembnih razlik med zdravilom Resolor in placebom v kateremkoli odmerku na podlagi povprečnih meritev QT in analize ubežnikov.
TQT study 
Podrobna študija QT
When breast-feeding, prucalopride can pass into breast milk. 
Pri dojenju prukaloprid lahko prehaja v materino mleko.